logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Growth Failure

    FiltersReset Filters
    4 results

    • ngenla

      (somatrogon-ghla)
      Pfizer Laboratories Div Pfizer Inc
      Usage: NGENLA is indicated for treating pediatric patients aged 3 years and older with growth failure resulting from inadequate secretion of endogenous growth hormone.

    • norditropin

      (somatropin)
      Novo Nordisk
      Usage: NORDITROPIN is indicated for pediatric patients with growth failure from inadequate growth hormone secretion, short stature due to Noonan or Turner syndrome, short stature born SGA, Idiopathic Short Stature, and Prader-Willi syndrome. For adults, it is used to replace endogenous growth hormone in those with deficiency.

    • skytrofa

      (Lonapegsomatropin-tcgd)
      Ascendis Pharma Endocrinology, Inc.
      Usage: SKYTROFA (lonapegsomatropin-tcgd) is indicated for treating pediatric patients aged 1 year and older, weighing at least 11.5 kg, with growth failure caused by inadequate secretion of endogenous growth hormone (GH).

    • sogroya

      (somapacitan-beco)
      Novo Nordisk
      Usage: SOGROYA is indicated for treating pediatric patients aged 2.5 years and older with growth failure due to inadequate growth hormone secretion and for replacing endogenous growth hormone in adults with growth hormone deficiency.